Kadimastem’s experimental cell therapy — AstroRx — may slow disease progression in patients with amyotrophic lateral sclerosis (ALS), according to interim results in a first group of patients treated in a Phase 1/2a study. AstroRx consists of functional healthy astrocytes — cells that support and protect neurons…
AstroRx, ALS Cell Therapy, Shows Potential to Slow Progression, Early Trial Data Show
If you’ve ever used the drive-thru lane to order a meal, then you know that the experience can range from easy to downright annoying. My husband and I have suffered through fast-talking order-takers with squeaky voices, but when we encounter the dreaded malfunctioning speaker, we know that we’re in for…
Synchron Inc. has successfully completed the first brain implantation of the Stentrode as part of a clinical feasibility trial. The first-in-human study is designed to assess the potential of this technology to restore communication in patients who suffer from severe paralysis, including those with amyotrophic lateral sclerosis (ALS). The Stentrode…
The Sean M. Healey & AMG Center at Mass General has chosen five “promising” candidate treatments from among 30 applications to test in its first platform trial for amyotrophic lateral sclerosis (ALS). The platform trial — a type of a clinical study that tests the efficacy of multiple…
A toxin produced by algae may contribute to the development of amyotrophic lateral sclerosis (ALS) by lowering the stability of a protein in the brain, a new study suggests. Titled “β-Methylamino-L-alanine substitution of serine in SOD1 suggests a direct role in ALS etiology,” the study was…
Spoiler alert: This column describes plotlines from the film “The Art of Racing in the Rain.” Friday movie night has become our favorite pastime, as it’s something we can still enjoy as a family despite my husband Todd’s paralysis. We typically find a funny movie on Netflix or Amazon Prime.
Fight Motor Neuron Disease (FightMND) has awarded Clene Nanomedicine‘s Australian subsidiary $1.37 million AUD (approximately $924,000) to advance clinical studies of a new amyotrophic lateral sclerosis (ALS) candidate treatment. These funds will support a Phase 2 clinical trial, named RESCUE-ALS, that will assess the efficacy and safety…
Daiichi Sankyo is looking to market the amyotrophic lateral sclerosis (ALS) treatment Radicava (edaravone) in Brazil after reaching a licensing agreement with the therapy’s maker, Mitsubishi Tanabe Pharma. The company will submit a regulatory application through its local subsidiary, and expects to commercialize Radicava in the…
The U.S. Federal Trade Commission (FTC) sent warning letters to three companies that sell cannabis-based products containing cannabidiol (CBD), cautioning them that making unsubstantiated claims about the health benefits of CBD could lead to legal action. The agency “urges the companies to review all claims made for…
My husband and I recently took a short trip out of town. On the morning we left, it dawned on me that I was going to have one of those days. You know the kind. A day when one thing after another gets in the way. The culminating moment happened…
Recent Posts
- Expanded access program for ALS drug MN-166 at 50% enrollment
- US clinical trials lack diverse representation of ALS patients
- Scientists grow specialized motor neurons to aid in ALS research
- ALS broke my independent streak and taught me how to ask for help
- Viral infection triggers ALS-like disease in mice with specific genes